Prestige Consumer Healthcare (NYSE:PBH) Given New $97.00 Price Target at Royal Bank of Canada

Prestige Consumer Healthcare (NYSE:PBH) had its price objective hoisted by Royal Bank of Canada from $96.00 to $97.00 in a report published on Friday morning,Benzinga reports. The firm currently has a sector perform rating on the stock.

A number of other brokerages have also recently commented on PBH. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Canaccord Genuity Group increased their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Oppenheimer increased their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Finally, DA Davidson increased their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $93.33.

Prestige Consumer Healthcare Stock Performance

PBH opened at $84.12 on Friday. The stock has a market cap of $4.17 billion, a P/E ratio of 19.70, a P/E/G ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock’s 50 day simple moving average is $82.46 and its 200 day simple moving average is $78.59. Prestige Consumer Healthcare has a 1-year low of $62.35 and a 1-year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, equities analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Kestra Investment Management LLC purchased a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth $27,000. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $40,000. McIlrath & Eck LLC lifted its stake in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock worth $75,000 after purchasing an additional 154 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth about $93,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.